Evidence map›Paper›PMID 33884024›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Chinese Herbal Medicine, Guilu Erxian Glue, as Alternative Medicine for Adverse Side Effects of Chemotherapy in Doxorubicin-Treated Cell and Mouse Models.

Chia-Ying Lien, Chen-Wen Lu, Yi-Hsuan Lin, Wan-Jhen Wu, Chih-Hsiang Hsu, Tai-Yuan Chuang, Kuei-Fu Lin, Wu-Chang Chuang, Ming-Chung Lee, Chung-Hsin Wu

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Therapeutic Effects of Plant Extracts ofPlants (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Traditional Chinese MedicineEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chia-Ying LienDepartment of Athletics, National Taiwan University, Taipei, Taiwan.
Chen-Wen LuSchool of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Yi-Hsuan LinDepartment of Physical Education, National Tsing Hua University, Hsinchu, Taiwan.
Wan-Jhen WuSchool of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Chih-Hsiang HsuSchool of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Tai-Yuan ChuangDepartment of Athletics, National Taiwan University, Taipei, Taiwan.
Kuei-Fu LinDepartment of Physical Education, National Tsing Hua University, Hsinchu, Taiwan.
Wu-Chang ChuangSun Ten Pharmaceutical Co. Ltd., New Taipei, Taiwan.
Ming-Chung LeeBrion Research Institute of Taiwan, New Taipei, Taiwan.
Chung-Hsin WuSchool of Life Science, National Taiwan Normal University, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-4470-2448
National Taiwan Normal University · TWNational Taiwan University · TWNational Tsing Hua University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX), a chemotherapeutic drug, often causes many adverse side effects in patients with cancer, such as weight loss, motor disability, blood circulation defects, myelosuppression, myocardial injury, joint degeneration, and bone loss. The Chinese herbal medicine Guilu Erxian Glue (GEG) has been used in the prevention and treatment of osteoarthritis and osteoporosis for hundreds of years, with considerably fewer side effects. We expected that GEG could serve as a protective and beneficial alternative treatment for DOX-induced adverse side effects. In this study, we evaluated whether GEG can alleviate DOX-induced weight loss, motor disability, abnormal blood circulation, myelosuppression, myocardial injury, joint degeneration, and bone loss by using chemotherapy models of synoviocyte cell line HIG-82 and mice. Moreover, we examined the antioxidant capacity of GEG by using DPPH (1,1-diphenyl-2-picrylhydrazyl) free-radical scavenging. Our results revealed that GEG treatment can significantly enhance DPPH free-radical scavenging and reduce DOX-induced cytotoxicity in synoviocyte HIG-82 cells. In addition, GEG treatment for 2 weeks can significantly relieve weight loss, enhance exhaustive exercise capacity, improve blood circulation, alleviate myocardial oxidative stress and inflammation, and strengthen the tibias of DOX-treated mice. Thus, we suggest that GEG treatment can be a protective and alternative therapy for alleviating chemotherapy-related side effects such as weight loss, motor disability, blood circulation defects, and bone loss.

Identifiers

PMID33884024
PMCPMC8041540
OpenAlexW3143427557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.